<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Grübler MR</dc:creator>
  <dc:creator>Gaksch M</dc:creator>
  <dc:creator>Kienreich K</dc:creator>
  <dc:creator>Verheyen ND</dc:creator>
  <dc:creator>Schmid J</dc:creator>
  <dc:creator>Müllner C</dc:creator>
  <dc:creator>Richtig G</dc:creator>
  <dc:creator>Scharnagl H</dc:creator>
  <dc:creator>Trummer C</dc:creator>
  <dc:creator>Schwetz V</dc:creator>
  <dc:creator>Meinitzer A</dc:creator>
  <dc:creator>Pieske B</dc:creator>
  <dc:creator>März W</dc:creator>
  <dc:creator>Tomaschitz A</dc:creator>
  <dc:creator>Pilz S</dc:creator>
  <dc:date>2018</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">BACKGROUND AND AIMS
Accumulating evidence has proposed a correlation between vitamin D (25(OH)D) insufficiency and cardiovascular (CV) disease. Vitamin D associated effects on endothelial function have been suggested to be a possible culprit. The present study investigated the association of vitamin D3 treatment on markers of endothelial dysfunction in patients with arterial hypertension.


METHODS AND RESULTS
The Styrian Vitamin D Hypertension Trial is a double-blind, placebo-controlled, single-centre study conducted at the Medical University of Graz, Austria. A total of 200 study participants with arterial hypertension and 25(OH)D levels below 30ng/mL were enrolled. The study participants were randomized to receive 2800 IU of vitamin D3 per day as oily drops (n=100) or placebo (n=100) for a duration of eight weeks. The present study uses an analysis of covariance (ANCOVA) to investigate the effect of vitamin D3 treatment on symmetric (SDMA) and asymmetric dimethylarginine (ADMA). A total of 187 participants (mean [SD] age 60.0 [11.3] years; 47% women; 25(OH)D 21.2 [5.6]ng/mL; mean systolic blood pressure of 131.4 [8.9] mmHg on a median of 2 antihypertensive drugs) completed the trial. Mean treatment effect was -0.004 (95%CI [-0.03 to 0.04]; P=0.819) on ADMA and 0.001 (95%CI [-0.05 to 0.05]; P=0.850) on SDMA. In the subgroup analysis patients with a 25(OH)D concentration &lt;20ng/mL had a significant increase in their log l-arginine/ADMA ratio (mean treatment effect 18.4 95%CI [1.84-34.9]μmol/L/μmol/L; P=0.030). ClinicalTrials.gov Identifier: NCT02136771 EudraCT number: 2009-018125-70 CONCLUSIONS: Vitamin D3 supplementation in hypertensive patients with low 25-hydroxyvitamin D has no significant effect on ADMA and SDMA.</dc:description>
  <dc:identifier>https://sonar.ch/global/documents/278660</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jsbmb.2016.12.014</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/28027911</dc:relation>
  <dc:source>The Journal of steroid biochemistry and molecular biology. - 2018</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Arterial hypertension</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Cardiovascular disease</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Endocrinology</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Endothelial dysfunction</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Vitamin D</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Vitamin D deficiency</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">Aged</dc:subject>
  <dc:subject xmlns:ns8="xml" ns8:lang="en">Analysis of Variance</dc:subject>
  <dc:subject xmlns:ns9="xml" ns9:lang="en">Arginine</dc:subject>
  <dc:subject xmlns:ns10="xml" ns10:lang="en">Blood Pressure</dc:subject>
  <dc:subject xmlns:ns11="xml" ns11:lang="en">Cholecalciferol</dc:subject>
  <dc:subject xmlns:ns12="xml" ns12:lang="en">Dietary Supplements</dc:subject>
  <dc:subject xmlns:ns13="xml" ns13:lang="en">Double-Blind Method</dc:subject>
  <dc:subject xmlns:ns14="xml" ns14:lang="en">Female</dc:subject>
  <dc:subject xmlns:ns15="xml" ns15:lang="en">Humans</dc:subject>
  <dc:subject xmlns:ns16="xml" ns16:lang="en">Hypertension</dc:subject>
  <dc:subject xmlns:ns17="xml" ns17:lang="en">Male</dc:subject>
  <dc:subject xmlns:ns18="xml" ns18:lang="en">Middle Aged</dc:subject>
  <dc:subject xmlns:ns19="xml" ns19:lang="en">Vitamin D</dc:subject>
  <dc:subject xmlns:ns20="xml" ns20:lang="en">Vitamin D Deficiency</dc:subject>
  <dc:title xmlns:ns21="xml" ns21:lang="en">Effects of Vitamin D3 on asymmetric- and symmetric dimethylarginine in arterial hypertension.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
